CSIMarket Company Name, Ticker, Customers, else..
 
Calidi Biotherapeutics Inc   (NYSEAMER: CLDI)
 
Price: $1.3500 $0.01 0.746%
Day's High: $1.3799999952316284 Week Perf: 2.27 %
Day's Low: $ 1.32 30 Day Perf: -23.3 %
Volume (M): 23,575 52 Wk High: $ 1.91
Volume (M$): $ 0 52 Wk Avg: $0.88
Open: $1.33 52 Wk Low: $0.09



 Market Capitalization (Millions $) 2
 Shares Outstanding (Millions) 1
 Employees 29
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -18
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Business Description


Calidi Biotherapeutics Inc is a biotechnology company that focuses on developing innovative cellular therapies for cancer treatment. They specialize in utilizing the power of oncolytic viruses to target and destroy cancer cells while preserving healthy cells. By engineering the viruses to specifically target tumors, Calidi Biotherapeutics aims to provide effective and personalized cancer treatments with minimal side effects. Their research and development efforts are centered around creating novel therapies that can potentially revolutionize cancer treatment and improve patient outcomes.


   Company Address: 4475 Executive Drive San Diego 92121 CA
   Company Phone Number: 794-9600   Stock Exchange / Ticker: NYSEAMER CLDI


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
IBRX   -2.5%    
IVVD   -7.22%    
MRNA        4.27% 
STRO   -3.61%    
TIL   -2.54%    
VXRT   -1.5%    
• View Complete Report
   



Shares

Calidi Biotherapeutics Strengthens Cash Reserves with New Investor Agreement, Advancing Targeted Immunotherapy Efforts,

Published Fri, Mar 28 2025 1:00 PM UTC

Calidi Biotherapeutics Expands Its Horizons with New Securities Agreement: A Step Forward in Targeted Immunotherapy DevelopmentIn a move signaling confidence from investors in the field of innovative cancer therapies, Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI), a clinical-stage biotechnology company based in San Diego, announced today the execution of a definitive se...
Shares

Calidi Biotherapeutics Seizes Funding Opportunity: $4.25 Million to Propel Targeted Cancer Therapy Development,

Published Fri, Jan 10 2025 1:30 PM UTC

Calidi Biotherapeutics Secures $4.25 Million in Public Offering: Accelerating the Future of Targeted Cancer TherapiesOn January 10, 2025, Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI), a clinical-stage biotechnology company focused on developing advanced immunotherapy treatments for cancer, announced the successful pricing of a public offering. The offering encompasses ...
Financing Agreement

Calidi Biotherapeutics Secures $4.25 Million in Public Offering: Accelerating the Future of Targeted Cancer Therapies,

Published Fri, Jan 10 2025 9:30 PM UTC

Calidi Biotherapeutics: Navigating the Future of Cancer Therapy with New Funding and Promising Advances in VirotherapySAN DIEGO, Jan. 10, 2025 Calidi Biotherapeutics Inc. (NYSE American: CLDI), a pioneering clinical-stage biotechnology company, has recently announced the successful closure of its public offering of 5,000,000 shares of common stock at $0.85 per share, enab...
Product Service News

Unleashing the Future of Cancer Care How Calidi Biotherapeutics RTNova Technology is Targeting Metastatic Lung Cance...

Published Mon, Nov 18 2024 1:00 PM UTC

Revolutionizing Targeted Cancer Therapy: Calidi Biotherapeutics Promising Data on RTNova Technology for Metastatic Lung Cancer In recent years, the field of oncology has witnessed remarkable advancements in targeted therapies that aim to improve patient outcomes while minimizing systemic toxicity. Among the companies at the forefront of this innovation is Calidi Biotherapeu...
Shares

Calidi Biotherapeutics Secures $7.5 Million from Public Offering to Propel Antitumor Virotherapy Development,

Published Fri, Nov 15 2024 9:05 PM UTC

Calidi Biotherapeutics Reaches Financial Milestone with $7.5 Million Public Offering: A Strategic Move in Targeted Antitumor VirotherapiesSan Diego-based Calidi Biotherapeutics Inc. (NYSE American: CLDI), a forward-thinking clinical-stage biotechnology firm, has recently closed a significant public offering, heralding potential advancements in their development of innovative...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 0.61
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.33
Working Capital Ratio 1.33
Leverage Ratio (MRQ) 1.3
Total Debt to Equity 0.21
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -60.22 $
Revenues (TTM) -
Cash Flow (TTM) 1.04 $
Cash 3.03 $
Book Value 2.21 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -603,724
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.